Rhythm Pharmaceuticals, Inc. RYTM License revenue — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s license revenue — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s license revenue — total revenues?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported license revenue — total revenues of $0 in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s license revenue — total revenues changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s license revenue — total revenues increased by 100.0% year-over-year, from -$5.01M to $0.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s license revenue — total revenues?
- Over 2 years (2022 to 2024), Rhythm Pharmaceuticals, Inc.'s license revenue — total revenues has grown at a -100.0% compound annual growth rate (CAGR), from $6.8M to $0.
- What does license revenue — total revenues mean?
- This metric represents the revenue generated from licensing intellectual property, technology, or drug candidates to third-party partners. It reflects the company's ability to monetize its research and development pipeline through strategic partnerships rather than direct product sales. Fluctuations in this metric indicate the timing and success of milestone payments, upfront fees, or royalty arrangements within the biopharmaceutical business model.